Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 72.5
(0.0%)
INR 72.5
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 452.15 Million INR | -44.43% |
| 2022 | 387.55 Million INR | 14.48% |
| 2021 | 338.54 Million INR | 31.41% |
| 2020 | 257.62 Million INR | 66.76% |
| 2019 | 154.48 Million INR | 75.76% |
| 2018 | 87.89 Million INR | 168.07% |
| 2017 | 32.78 Million INR | -54.38% |
| 2016 | 71.87 Million INR | -42.04% |
| 2015 | 124.01 Million INR | 106.27% |
| 2014 | 60.12 Million INR | -87.92% |
| 2013 | 497.51 Million INR | 16.08% |
| 2012 | 428.59 Million INR | 55.13% |
| 2011 | 276.27 Million INR | 73.37% |
| 2010 | 159.35 Million INR | 30.54% |
| 2009 | 122.07 Million INR | 5.62% |
| 2008 | 115.58 Million INR | 303.15% |
| 2007 | 28.66 Million INR | 38.45% |
| 2006 | 20.7 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 16.09 Million INR | -75.28% |
| 2023 Q2 | 118.84 Million INR | -22.65% |
| 2023 Q4 | 65.12 Million INR | 26.44% |
| 2023 FY | 215.35 Million INR | -44.43% |
| 2023 Q3 | 51.5 Million INR | -56.66% |
| 2023 Q1 | 153.64 Million INR | 6.68% |
| 2022 FY | 387.55 Million INR | 14.48% |
| 2022 Q1 | 64.76 Million INR | 21.4% |
| 2022 Q2 | 81.72 Million INR | 26.2% |
| 2022 Q3 | 97.05 Million INR | 18.75% |
| 2022 Q4 | 144.01 Million INR | 48.39% |
| 2021 Q4 | 53.34 Million INR | -33.99% |
| 2021 Q1 | 81.79 Million INR | -11.06% |
| 2021 FY | 338.54 Million INR | 31.41% |
| 2021 Q2 | 122.6 Million INR | 49.89% |
| 2021 Q3 | 80.81 Million INR | -34.09% |
| 2020 Q1 | 49.98 Million INR | -40.83% |
| 2020 FY | 257.62 Million INR | 66.76% |
| 2020 Q4 | 91.96 Million INR | 46.19% |
| 2020 Q3 | 62.9 Million INR | 19.23% |
| 2020 Q2 | 52.76 Million INR | 5.54% |
| 2019 Q1 | 5.06 Million INR | -89.2% |
| 2019 FY | 154.48 Million INR | 75.76% |
| 2019 Q4 | 84.48 Million INR | 122.71% |
| 2019 Q3 | 37.93 Million INR | 40.47% |
| 2019 Q2 | 27 Million INR | 433.06% |
| 2018 Q2 | 31.86 Million INR | 53.43% |
| 2018 FY | 87.89 Million INR | 168.07% |
| 2018 Q4 | 46.89 Million INR | 12.62% |
| 2018 Q3 | 41.64 Million INR | 30.69% |
| 2018 Q1 | 20.76 Million INR | 0.0% |
| 2017 FY | 32.78 Million INR | -54.38% |
| 2016 FY | 71.87 Million INR | -42.04% |
| 2015 FY | 124.01 Million INR | 106.27% |
| 2014 FY | 60.12 Million INR | -87.92% |
| 2013 FY | 497.51 Million INR | 16.08% |
| 2012 Q1 | 105.29 Million INR | 0.0% |
| 2012 Q2 | 45.58 Million INR | -56.71% |
| 2012 Q3 | 103.09 Million INR | 126.16% |
| 2012 Q4 | 135.52 Million INR | 31.45% |
| 2012 FY | 428.59 Million INR | 55.13% |
| 2011 FY | 276.27 Million INR | 73.37% |
| 2010 FY | 159.35 Million INR | 30.54% |
| 2009 FY | 122.07 Million INR | 5.62% |
| 2008 FY | 115.58 Million INR | 303.15% |
| 2007 FY | 28.66 Million INR | 38.45% |
| 2006 FY | 20.7 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 98.312% |
| Hester Biosciences Limited | 1.27 Billion INR | 64.499% |
| Aarti Drugs Limited | 8.31 Billion INR | 94.563% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 92.246% |
| Albert David Limited | 1.4 Billion INR | 67.889% |
| Alembic Limited | 1 Billion INR | 54.79% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.135% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 69.279% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -3504.249% |
| Brooks Laboratories Limited | 65.62 Million INR | -589.048% |
| Eris Lifesciences Limited | 10.42 Billion INR | 95.664% |
| FDC Limited | 6.58 Billion INR | 93.135% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 96.363% |
| Gufic Biosciences Limited | 4.07 Billion INR | 88.901% |
| Hikal Limited | 5.95 Billion INR | 92.411% |
| Ind-Swift Limited | 2.17 Billion INR | 79.188% |
| Innova Captab Limited | 3.46 Billion INR | 86.949% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 90.419% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 30.714% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 97.698% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 76.037% |
| Lupin Limited | 125.09 Billion INR | 99.639% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | 34.584% |
| Medico Remedies Limited | 262.14 Million INR | -72.483% |
| Morepen Laboratories Limited | 6.16 Billion INR | 92.661% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 90.626% |
| Orchid Pharma Limited | 2.32 Billion INR | 80.513% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 92.179% |
| RPG Life Sciences Limited | 2.48 Billion INR | 81.79% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 27.128% |
| Sigachi Industries Limited | 2 Billion INR | 77.418% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 127.306% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 89.034% |
| Themis Medicare Limited | 2.42 Billion INR | 81.316% |
| Unichem Laboratories Limited | 4.86 Billion INR | 90.706% |
| Vaishali Pharma Limited | 90.32 Million INR | -400.596% |
| Wanbury Limited | 1.73 Billion INR | 73.874% |
| Windlas Biotech Limited | 1.33 Billion INR | 66.227% |
| ZIM Laboratories Limited | 1.26 Billion INR | 64.336% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 89.061% |
| Ipca Laboratories Limited | 48.58 Billion INR | 99.069% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.825% |
| Venus Remedies Limited | 2.18 Billion INR | 79.284% |
| Sakar Healthcare Limited | 699.58 Million INR | 35.368% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 99.587% |
| Divi's Laboratories Limited | 32.44 Billion INR | 98.606% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 92.734% |
| Mankind Pharma Limited | 42.19 Billion INR | 98.928% |
| Sequent Scientific Limited | 2.97 Billion INR | 84.821% |
| Laurus Labs Limited | 15.44 Billion INR | 97.073% |
| Neuland Laboratories Limited | 8.24 Billion INR | 94.518% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 97.037% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.348% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.639% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 78.408% |
| Wockhardt Limited | 7.72 Billion INR | 94.143% |
| Bal Pharma Limited | 770.19 Million INR | 41.294% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.724% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 87.765% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | 14.549% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 95.089% |
| Shilpa Medicare Limited | 3.56 Billion INR | 87.306% |
| Valiant Laboratories Limited | 138.02 Million INR | -227.578% |
| Ajanta Pharma Limited | 21.06 Billion INR | 97.853% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -300.033% |
| Granules India Limited | 16.79 Billion INR | 97.308% |
| Medicamen Biotech Limited | 495.49 Million INR | 8.747% |
| Syncom Formulations (India) Limited | 559.5 Million INR | 19.187% |
| Piramal Enterprises Limited | 8.04 Billion INR | 94.379% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.033% |
| NATCO Pharma Limited | 25.73 Billion INR | 98.243% |
| Suven Life Sciences Limited | -200.79 Million INR | 325.179% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 515.784% |
| Strides Pharma Science Limited | 14.38 Billion INR | 96.857% |
| Indoco Remedies Limited | 8.04 Billion INR | 94.378% |
| Alpa Laboratories Limited | 188.89 Million INR | -139.367% |
| Lasa Supergenerics Limited | 121.02 Million INR | -273.588% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -15.621% |